%PDF-1.4
%
46 0 obj
<>
endobj
43 0 obj
<>
endobj
97 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-09-08T17:40:58Z
2024-03-28T05:18:30-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T05:18:30-07:00
application/pdf
Heather
2002-530.oct
uuid:073f81b7-1dd2-11b2-0a00-230927fd5800
uuid:073f81b9-1dd2-11b2-0a00-6a0000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
111 0 obj
[115 0 R]
endobj
112 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
10 0 0 10 54 713.1616 Tm
(H)Tj
6.5 0 0 6.5 61.2192 709.8616 Tm
(2)Tj
-0.00011 Tc 0.10941 Tw 10 0 0 10 68.0636 713.1616 Tm
(blockers, proton-pump inhibitors\), or to use alternative)Tj
0.0686 Tw -1.4064 -1.2 Td
(types of drugs. Future studies, using these risk models, are)Tj
0.22771 Tw 0 -1.2 TD
(needed to define which alternative therapies provide the)Tj
0.00951 Tw T*
(most benefit for high risk patients. Use of the SCORE)Tj
0 Tc 0 Tw 6.5 0 0 6.5 270.91 680.4615 Tm
(\251)Tj
-0.00011 Tc 10 0 0 10 278.4434 677.1616 Tm
(tool)Tj
-22.4443 -1.2 Td
(and )Tj
/T1_1 1 Tf
0 Tc 1.826 0 Td
(e)Tj
/T1_0 1 Tf
-0.00011 Tc 0.1321 Tw [0.2 (SCORE represents a potential method for predicting)]TJ
0.02499 Tw -1.826 -1.2 Td
(NSAID risk before the patient takes the medication.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 619.1616 Tm
[(1.)-875.1 (Grif)17.7 (fin MR. Epidemiology of nonsteroidal anti-inflammatory )]TJ
1.675 -1.25 Td
[(drug-associated gastrointestinal injury)64.8 (. )54.8 (Am J Med )]TJ
0 Tc 0 Tw 0 -1.25 TD
(1998;104:23S-29S.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Schoenfeld P)110.7 (, Kimmey MB, Scheiman J, Bjorkman D, Laine L.)]TJ
1.675 -1.25 Td
(Review article: nonsteroidal anti-inflammatory drug-associated)Tj
T*
(gastrointestinal complications-guidelines for prevention and )Tj
T*
[(treatment. )54.8 (Aliment Pharmacol )17.7 (Ther 1999;13:1273-85.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (W)79.9 (olfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of)]TJ
1.675 -1.25 Td
(nonsteroidal antiinflammatory drugs. N Engl J Med )Tj
0 Tc 0 Tw T*
(1999;340:1888-99.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious)]TJ
1.675 -1.25 Td
(gastrointestinal complications related to use of nonsteroidal )Tj
T*
[(antiinflammatory drugs: a metaanalysis. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
[(1991;1)36.9 (15:787-96.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Henry D, Dobson )54.8 (A, )17.7 (T)35 (urner C. )17.7 (V)110.8 (ariability in the risk of major)]TJ
1.675 -1.25 Td
(gastrointestinal complications from nonaspirin nonsteroidal )Tj
T*
(anti-inflammatory drugs. Gastroenterology 1993;105:1078-88.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Hansen JM, Hallas J, Lauritsen JM, Bytzer P)110.7 (. Nonsteroidal )]TJ
1.675 -1.25 Td
(anti-inflammatory drugs and ulcer complications: a risk factor)Tj
T*
(analysis for clinical decision making. Scand J Gastroenterol)Tj
0 Tc 0 Tw 33 35.671 Td
(1996;31:126-30.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Carson JL, Strom BL, Morse L, et al. )17.7 (The relative gastrointestinal)]TJ
1.675 -1.25 Td
[(toxicity of the nonsteroidal anti-inflammatory drugs. )54.8 (Arch Intern)]TJ
0 Tc T*
(Med 1987;147:1054-9.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Savage RL, Moller PW)91.7 (, Ballantyne CL, )17.7 (W)79.9 (ells JE. )17.7 (V)110.8 (ariation in the)]TJ
1.675 -1.25 Td
(risk of peptic ulcer complications with nonsteroidal )Tj
T*
[(anti-inflammatory drug therapy)64.8 (. )54.8 (Arthritis Rheum 1993;36:84-90.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Langman MJS, )17.7 (W)79.9 (eil J, )17.7 (W)79.9 (ainwright P)110.7 (, et al. Risks of bleeding peptic)]TJ
1.675 -1.25 Td
(ulcer associated with individual nonsteroidal anti-inflammatory)Tj
T*
(drugs. Lancet 1994;343:1075-8.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Kaufman DW)91.7 (, Kelly JP)110.7 (, Sheehan JE, et al. Nonsteroidal anti-)]TJ
2.175 -1.25 Td
(inflammatory drug use in relation to major upper gastrointestinal)Tj
T*
[(bleeding. Clin Pharmacol )17.7 (Ther 1993;53:485-94.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Rodriguez LAG. )17.7 (V)110.8 (ariability in risk of gastrointestinal complications)]TJ
2.1381 -1.25 Td
[(with dif)17.7 (ferent nonsteroidal anti-inflammatory drugs. )54.8 (Am J Med)]TJ
0 Tc 0 Tw T*
(1998;104:30S-34S.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Fries JF)79.7 (, )17.7 (W)39.9 (illiams CA, Bloch DA, Michel BA. Nonsteroidal )]TJ
2.175 -1.25 Td
(anti-inflammatory drug associated gastropathy: incidence and risk)Tj
T*
[(factor model. )54.8 (Am J Med 1991;91:213-22.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Singh G, Ramey DR, )17.7 (T)35 (riadafilopoulus G, Brown BW)91.7 (, Balise RR.)]TJ
2.175 -1.25 Td
[(GI SCORE: )54.8 (A)-220.1 (simple self-assessment instrument to quantify the)]TJ
T*
[(risk of serious NSAID-related GI complications in RA)-220.2 (and OA)]TJ
T*
[([abstract]. )54.8 (Arthritis Rheum 1998;41 Suppl:S75.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (The California REDUCE Coalition \(American Gastroenterological)]TJ
2.175 -1.25 Td
(Association, et al.\). Do you know your SCORE? November 1998.)Tj
T*
[([Cited June 16, 2003] )54.8 (A)73.9 (vailable from: http://mednews.stanford.edu/)]TJ
T*
[(news_releases_html/1998/novreleases/singh1)36.8 (198.html. SCORE)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 542.4828 457.1693 Tm
(\251)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 338.4 444.5293 Tm
[(T)69.9 (ool available from: www)64.8 (.mplan.com/pdf/score.pdf)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2244)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>stream
8;Z\6MfQ]X%.jN!TRUSp+Bo=$+b\Zg46tUR2W0?A9N2[^56WKL[gk5`Ao7A'hU_F$
lK.Wf3iS-]_SO&/CfNQ.:kQ95uZqGEaAh$j!JNE+67Ass3:GC:S,_DdmP!P>Na=]@k2HVci"kJFj@q9GO
`Y#mn]->1\V*0.bf_oK&ePi/BEFW.V6%mHb0s>mu>m-4G"t.gJCgKTWHU:81i.Mi#
OA1*ZIELOr1tbW]3%%e9dC/(."B#@Q=Y\N1j*%3MbeR
2G\"[1/Xh9M.0;nSpA$2hT^kd:Yu(/QX:Qm?""2d4oOK'SSC6C(*+HaU2Do'3aNe^
r&E(RGBo:'"4Zr_F7dmh)kNlrEQ,r-!YQ2,IC"nGM*rPM80eh)6mD0%+O@=3aGn/E
ffbfV-'^7\fsq#=^'4S>7
endstream
endobj
30 0 obj
[/Indexed/DeviceRGB 255 29 0 R]
endobj
29 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
53 0 obj
<>
endobj
50 0 obj
<>
endobj
61 0 obj
<>
endobj
88 0 obj
<>
endobj
102 0 obj
<>
endobj
62 0 obj
<>
endobj
78 0 obj
<>stream
HLPw9v_lEY=I1s_U J 'J Gppmww`P "FaAFEL:N4IZkHgfgwyg>wI"< I2jMEglVFBGdN'9x?~⎐i5:"(8(?c2-Yl2%rUַ˅b%Iq/h5qMjIH-tl뫜Ra/pe\n)\,6up
9ETO+N,BKY,EB(*/ f{Q[BYZ?\>z4AA,1$#YꈈpfbK֓߇m {?.SץSpҨP^}_w:%]2l?abh4ƚk[$d
l
~ȶ=6ARқZƾ]ZNQ0|upw+3.K:e!`XRh[qp{=@Xv`G-neٶ^XbEx6-8p"kY<)pBA<42> 0A&M8|ft݀/
\LOpti)j»m;7{Ы~P @Kc{}lȍ^ys</(i-\-Ƹ